Eli Lilly and Company's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19
Posted:
FDA has authorized bebtelovimab for emergency use for certain non-hospitalized patients with mild-to-moderate COVID-19 at high risk of progression to severe disease for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate Bebtelovimab neutralizes Omicron as demonstrated by pseudovirus and authentic virus data.
The patients who watched the personalized AI avatar videos showed better understanding of their treatment plan, a greater ability to engage with health care decisions, and reduced stress compared to those who watched the standard educational video.
Read more here.
Once cancer has begun to spread within the body (metastasise) it generally becomes harder to treat and survival rates are lower. The new research focuses on patients with oligometastatic breast cancer, meaning a few small secondary tumors have broken away…
Attendees
Sponsors and Exhibitors
Contact us